The "Checkpoint Inhibitor Refractory Cancer Drugs Market – Growth, Share, Opportunities & Competitive Analysis, 2025 – 2032" report has been added to the Credence Research Inc. offering.

Mezigdomide (a CELMoD) combined with carfilzomib/dexamethasone met the phase 3 primary endpoint, delivering statistically ...

In this phase 2 study, researchers aimed to evaluate the effectiveness of tyrosine kinase inhibition in relapsed or refractory germ cell tumors.

The "Checkpoint Inhibitor Refractory Cancer Drugs Market - Growth, Share, Opportunities & Competitive Analysis, 2025 - 2032" report has been added to the ...

CAR T-cell immunotherapy improved progression-free and overall survival in patients with relapsed or refractory marginal zone ...

New ASH guidelines outline optimal management for a subgroup of patients with leukemia that historically has been challenging to treat.Two papers published simultaneously in Blood Advances address ...

Bristol Myers Squibb said its treatment candidate for certain blood cancers performed well in a late-stage trial.

The recent FDA approval of teclistamab (Tecvayli) in combination with daratumumab and hyaluronidase-fihj (Darzalex Faspro), both from Janssen Biotech, Inc, marks a significant shift in treating ...

ANI Pharmaceuticals (NASDAQ:ANIP) executives used a presentation at the Leerink Partners Global Healthcare Conference to outline the company’s recent performance, 2026 financial outlook, and ...

Therapies backed only by lower-tier evidence no better than unmatched treatment ...

A two-step approach pooled indication-specific response rates, then generated naïve odds ratios via random-effects models, reflecting limited head-to-head evidence across BTK inhibitors. Across ...

Setting The outpatient wound care department of the Affiliated Jiangsu Shengze Hospital of Nanjing Medical University from August 2019 to June 2020. Participants Sixty patients were enrolled in this ...